New Malaria Lead Compound Identified

  • Author: David Bradley
  • Published: 04 March 2012
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
  • Source / Publisher: ACS Medicinal Chemistry Letters/ACS Publications
thumbnail image: New Malaria Lead Compound Identified

Researchers at GlaxoSmithkline (GSK) in Madrid, Spain, and their colleagues have identified 47 quality starting points for pharmaceutical lead optimization for new antimalarial drugs. The team searched the GSK database of 13,533 chemical structures published in 2010.

One of the most promising compounds was TCMDC-139046, which has an indoline core, and is known to have anxiolytic activity through its interaction with serotonin antagonist receptors 5-HT2. If it were to be used as an antimalarial, it would have side-effects because of this activity. As such, the GSK team working with the Medicines for Malaria Venture (MMV), Geneva, Switzerland, have used a double-divergent structure–activity relationship (SAR) study to home in on a chemical cousin that lacks the receptor activity but works as an antimalarial. They found better selectivity was obtained with the piperidine derivatives (pictured), where no interaction with 5-HT2c was detected and the activity against multidrug resistant malarial strains was maintained.

Article Views: 3959

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

If you would like to reuse any content, in print or online, from, please contact us first for permission. more

CONNECT: on Facebook on Twitter on YouTube on LinkedIn Sign up for our free newsletter

Magazine of Chemistry Europe (16 European Chemical Societies)published by Wiley-VCH